Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 27

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 27
---
 Reclassification
    of earnout liability 
     -  
     -  
     -  
     -  
     (4,900,000) 
     -  
     -  
     (4,900,000)
  
    Conversion
    of CERo bridge notes and accrued interest into Series A preferred stock 
     630  
     627,154  
     -  
     -  
     -  
     -  
     -  
     627,154 
  
    Conversion
    of working capital loan into Series A preferred stock 
     1,605  
     1,555,000  
     -  
     -  
     -  
     -  
     -  
     1,555,000 
  
    Issuance
    of Series A shares sold to investors, net 
     7,854  
     6,755,698  
     -  
     -  
     (856,663) 
     -  
     -  
     5,899,035 
  
    Issuance
    of Series A Preferred Warrants 
     -  
     -  
     -  
     -  
     2,000,000  
     (2,000,000) 
     -  
     - 
  
    Issuance
    of common shares to Keystone Capital LLC for equity line of credit 
     -  
     -  
     59  
     -  
     633,345  
     -  
     -  
     633,345 
  
    Opening
    Equity at February 14, 2024 (Successor) 
     10,089  
    $8,937,852  
     7,266  
    $1  
    $53,899,885  
    $(2,000,000) 
    $(63,185,641) 
    $(2,347,903)

NOTE
4 – NET LOSS PER SHARE OF COMMON STOCK

The
accounting standards require the presentation of both basic and diluted earnings per share on the face of the statements of operations.
The Company’s basic net loss per share is computed by dividing net